

Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair

Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model.

Bristol, UK, 28 April 2026 - eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, has appointed George Fotiades as Chair. The appointment brings extensive CDMO and healthcare leadership experience to the board as eXmoor enters its next phase of development, supported by a purpose-built GMP facility and a growing integrated delivery model spanning consultancy, process development and clinical manufacturing.

Angela Osborne, who founded eXmoor and has been central to its growth over more than two decades, will step back from all operational duties and will continue in her role as Founder and Board Director. She will remain actively involved in the strategic direction of the business and will continue to represent eXmoor across the wider cell and gene therapy ecosystem.

The appointment follows the recent addition of Manuel Balbuena as Chief Commercial Officer, further strengthening the leadership team as eXmoor scales its commercial and operational capacity.

About George Fotiades

George Fotiades brings decades of leadership experience across healthcare and life sciences, with a particular track record in building and scaling contract development and manufacturing businesses. He created Cardinal Health's Pharmaceutical Technologies and Services division, integrating more than ten acquired businesses into a single coherent organisation. That division subsequently became Catalent Pharma Solutions, where he served as Chair and CEO. He has since held leadership and board roles across private equity-backed and global healthcare businesses, and brings to eXmoor a deep understanding of what it takes to build operationally credible, growth-oriented CDMO organisations.

Lucy Foley, Chief Executive Officer of eXmoor Pharma, commented:

"We are building a leadership structure that reflects where eXmoor is going. George's appointment gives us board-level experience that is directly relevant to scaling a CDMO, where depth matters as we grow our GMP delivery capability and expand our partnerships across Europe and internationally. Angela's continuing involvement ensures our clients and collaborators have the continuity they expect from us. This is a strong foundation for the next chapter."

George Fotiades, Chair of eXmoor Pharma, said:

"Having worked across healthcare and life sciences businesses at scale, I have seen how rarely early-stage consultancy, process development and GMP manufacturing are genuinely integrated under one organisation. eXmoor has built that capability, and the client relationships to reflect it. I am excited to work alongside Lucy and the team to broaden our network, strengthen those partnerships, and to help take what has been built here to a wider market as the business grows."

Angela Osborne, Founder and Board Director of eXmoor Pharma, added:

"eXmoor has come a long way. We have built something genuinely distinctive in this sector, and the quality of the work we do for our clients is something I am enormously proud of. Appointing George as Chair is about adding the right experience at the right moment as we scale what we have built. He has grown CDMO businesses before and he understands the operational and commercial discipline that this involves. I look forward to working alongside George and Lucy in a part-time capacity as we move into the next chapter."

About eXmoor Pharma

eXmoor Pharma is the only integrated cell and gene therapy CDMO with over 20 years of consultancy expertise embedded at every stage of development. From early-phase strategy and process development to GMP manufacturing and commercialisation, eXmoor supports clients with deep technical knowledge, regulatory insight and flexible manufacturing solutions. With a purpose-built facility in Bristol, UK, and over 190 clients globally, eXmoor partners with innovators to scale therapies safely and efficiently.